Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand

Executive Summary

Lilly is asking FDA to accept Yentreve as the trade name for duloxetine for the treatment of stress urinary incontinence
Advertisement

Related Content

Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer
Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer
Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA
Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA
Rx Labeling Should Be Left To Manufacturers, Not FDA, Pfizer Says
FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients
Advertisement
UsernamePublicRestriction

Register

PS042682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel